Study of High Efficient Killing Cell Therapy for Advanced NSCLC

NCT03193567 ↗

Phase 1 Recruiting 15 enrolled Ruijin Hospital Shanghai Houchao Biotechnology Co., Ltd · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer

Timeline

Start: 2017-09-14
Primary completion: 2025-05-01
Completion: 2025-05-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HEKT cell	Cell therapy	—	Other

Study of High Efficient Killing Cell Therapy for Advanced NSCLC

Summary

Timeline

Drugs

Indications